Vol.

No.

May 01, 2026May 01, 2026

DOWNLOAD THE PDF

Cover Story

By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel

Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”

By Claire Marie Porter

Health and Human Services Secretary Robert F. Kennedy Jr. is moving to overhaul the U.S. Preventive Services Task Force, a highly influential panel that determines which preventive services insurers must cover and guides routine medical care for millions of Americans.

Regulatory News

FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.”

By Sara Willa Ernst

Benjamin Ebert, Amy Gladfelter, Stephen Liberles, and Pardis Sabeti are among new members of the National Academy of Sciences

Podcast

Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time

Cancer Policy

CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show

Radiation oncologists urge lawmakers to act as Medicare cuts and private payer tactics push cancer clinics toward closing

In Brief

MD Anderson establishes Center for Cellular Language Intelligence with $10M gift

Siemens Healthineers awarded $60M by ARPA-H to advance photon flash radiotherapy for cancer care

UT San Antonio awarded $44M NIH contract to advance landmark RURAL Cohort Study

IARC marks 60th anniversary

UC Davis’ Frederick J. Meyers earns dual honors from the Association for Clinical and Translational Science

Clinical Roundup

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

Researchers from Wistar and ChristianaCare identify therapeutic target for pancreatic cancer

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

“Forever chemicals” may be linked to childhood leukemia, UC Irvine study finds

Eating primes immune cells for future responses, UPMC study finds

Drugs & Targets

ODAC recommends against approval of camizestrant NDA, gives a nod to sNDA for capivasertib

FDA accepts NDA for zipalertinib for NSCLC with mutations

FDA grants priority review for Ziihera in first-line HER2+ GEA

FDA approval of IDE supplement to expand Alpha DaRT IMPACT Trial to patients with pancreatic cancer receiving gemcitabine with abraxane

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

NCI Trials

NCI Trials for May 2026

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE